Refine
Document Type
- Doctoral Thesis (8)
Language
- English (8) (remove)
Has Fulltext
- yes (8)
Is part of the Bibliography
- no (8)
Keywords
Institute
Alzheimer’s disease is a chronic neurodegenerative disease that causes problems with memory, thinking and behavior. The pathophysiological hallmarks of AD are extracellular senile plaques and intracellular neurofibrillary tangles. Amyloid plaques mainly contain the amyloid-β (Aβ) peptide, which appears as a cleavage product of the APP. APP is a type I transmembrane protein with a large extracellular domain and a short cytoplasmic tail. It is expressed in variety of tissues e.g. in neuronal tissue (brain, spinal cord, retina), and non-neuronal tissues (kidney, lung, pancreas, prostate gland, and thyroid gland) (Dawkins and Small, 2014). APP has been studied because of its link to AD, however, its role in normal brain function is poorly understood. APP is processed by two different pathways, amyloidogenic pathway and non-amyloidogenic pathway. In physiological condition, the majority of APP is processed via the non-amyloidogenic, thus leading to the generation of the secreted N-terminal APP processing product sAPPα. sAPPα is formed due to the cleavage of APP by α-secretase. In previous studies, our group has shown that sAPPα produce potent neuroprotective effect by altering gene expression, as well as by antagonizing several different types of neurotoxic stress stimuli (Copanaki et al., 2010; Kögel et al., 2003, 2005; Milosch et al., 2014). Several studies have shown that protein degradation is reduced in AD (Hong et al., 2014; Lipinski et al., 2010) but the role of APP and its cleavage products in protein degradation is still unknown. This thesis discusses about the physiological functions of APP in neuroprotection and protein homeostasis.
In the first part of the thesis (Section 4.1 - 4.4), the neuroprotective properties of yeast derived sAPPα and E1 (N-terminal domain of sAPPα) were investigated under serum and glucose deprivation conditions. In previous work, it was shown that recombinant sAPPα evoked a significant decrease in serum deprivation triggered cell death in human SH-SY5Y neuroblastoma cells and mouse embryonic fibroblast MEF cells. It was also observed that sAPPα induces the phosphorylation of Akt which leads to neuroprotection (Milosch et al., 2014). This study investigated whether this neuroprotection is associated with altered expression of downstream intracellular Akt targets such as FoxO, Bim, Bcl-xL and Mcl-1 under stress conditions. Here it was shown that sAPPα prevents activation and nuclear translocation of FoxO. FoxO act as a transcription factor for different proapoptotic genes such as Bim. It was also observed that Bim protein and mRNA expression was significantly reduced with sAPPα and E1 treatment. The expression of antiapoptotic protiens such as Bcl-xL and Mcl-1 were also examined and it was observed that sAPPα and E1 increases expression of both these proteins. Furthermore, it was previously demonstrated that uncleaved holo-APP functionally cooperates with sAPPα to activate Akt and provide neuroprotection (Milosch et al., 2014). Therefore, to investigate the function of the APP in sAPPα regulated Akt downstream proteins expressions, MEF APP KO cells were used. E1 and sAPPα only showed neuroprotective modulatory effect on these Akt downstream targets in MEF wt cells, but not in APP KO cells. In addition, sAPPα also showed neuroprotection in primary wt hippocampal neurons under trophic factor deprivation. Cellular fractionation experiments were also done to determine the role of sAPPα in cytochrome c release from mitochondria. It was observed that sAPPα treatment can inhibit mitochondrial cytochrome c release in wt MEF cells.
The second part of the thesis (Section 4.5 - 4.9) discusses about the role of sAPPα in protein homeostasis. It was observed that sAPPα prevents proteotoxic stress induced BAG3 protein expression in SH-SY5Y and MEF cells. This was also observed in mRNA levels which indicate a transcriptional regulation. Furthermore, treatment with sAPPα was also shown to decrease aggresomes formation. Aggresomes are perinuclear aggregates which are formed due to accumulation of damaged and misfolded proteins and BAG3 plays important role in their formation and the transport of degradation prone proteins into these structures. The analysis of proteasomal activity showed a reduced accumulation of proteasomal substrate d2 by sAPPα under proteasomal stress. In proteasomal activity assay, sAPPα was shown to increase the degradation of proteasomal substrate SUC-LLVY-AMC and the fluorigenic signal was measured spectrophotometrically. The sAPPβ fragment which is generated via the amyloidogenic pathway was also examined for its role in BAG3 expression and proteasomal degradation. sAPPβ, which has almost similar structure as sAPPα, only 17 amino acids at the C-terminus is missing, was failed to modulate BAG3 expression and proteostasis. This indicates that these biological effects are highly specific for sAPPα.
...
Endocannabinoids (eCB) are signaling lipids and became known for their importance in the central nervous system as well as in immune defense. Beneficial effects of eCB are shown in processes of excitotoxic lesion, secondary damage and neuronal plasticity throughout the last years. Two canabinoid receptors, type 1 (CB1) and type 2 (CB2) as the respective endogenous ligands belong to the endocannabinoid system (eCBS). In 1990, the CB1 could be cloned and was localised mainly on neurons. Shortly thereafter in 1993, the CB2 was characterised and found primarily on cells belonging to the immune system. N-arachidonoylethanolamide (AEA), often called anandamide, and 2-arachidonoylglycerol (2-AG) are the best characterised eCB. N-palmitylethanolamide (PEA) and N-oleoylethanolamide (OEA) have no or only low affinity to CB1 but enhance the affinity of AEA significantly. This group is therefore often summarized as N-ethanolamides (NEA). ECB are derivates of arachidonic acid and are stored in membranes where they become hydrolysed on demand by specific enzymes. Traumatic brain injury altered the levels of eCB in the blood in vivo and when applied in vitro after neuronal damage, eCB could reduce the damaging burden. Further studies demonstrated that eCB are potent to down-regulate pro-inflammatory cytokines and most important to decrease neuronal excitation.
In the present study, the intrinsic regulation of the endocannabinoid system after neuronal damage over time was investigated in rat Organotypic Hippocampal Slice Cultures (OHSC). Temporal and spatial dynamics of eCB levels were analysed after transection of the perforant pathway (PPT) in originating neurons (enthorhinal cortex, EC), areas of deafferentiation/anterograde axonal degeneration (dentate gyrus, DG) and of the synaptically linked cornu ammonis region 1 (CA1) as well as after excitotoxic lesion in the respective regions.
A strong increase of all eCB was observed only in the denervation zone of the DG 24 hours post PPT. In excitotoxic lesioned OHSC all eCB were elevated, in the investigated regions up to 72 hours post lesion (hpl). The responsible enzyme for biosynthesis of the NEA, NAPE-PLD protein, was increased during the early timepoints of measurement (1-6 hpl). The responsible catabolizing enzyme, FAAH, and the CB1 receptor were up-regulated at a later timepoint, 48 hpl, explaining the eCB levels. In the present model, the inhibition of the enzyme responsible for 2-AG hydrolysis (MAGL) was neuroprotective as previously shown and a re-distribution within neurons and astrocytes during neuronal damage could be observed. In primary cell cultures microglia expressed the regulating enzymes of 2-AG and the enzyme responsible for NEA down-regulation, FAAH. Astrocytes expressed mainly the catalyzing enzymes, indicating the role for eCB break-down. All these findings together demonstrate the great capacity of the eCBS to control inflammatory processes and consequently neuronal cell death.
All effects of the known eCB could not be clarified by CB1/CB2 deficient mice. Several G-protein coupled receptors (GPR) are recently in discussion whether they might and should belong to the endocannabinoid system. The GPR55, the not yet cloned abnormal cannabidiol receptor and further GPRs are candidates as potential endocannabinoid receptors. Recently GPR55 has been discussed as a putative cannabinoid receptor type 3 (CB3). Quantitative PCR revealed that Gpr55 is present in primary microglia and the brain, but the exact regional and cellular distribution and the physiological/pathological effects downstream of GPR55 activation in the CNS still remain open. Therefore, the excitotoxic rat OHSC model, previously used to investigate the neuroprotective potency of eCB, was now used to investigate the neuroprotective potency of GPR55. Activation of GPR55 protected dentate gyrus granule cells in vitro after excitotoxic lesion, induced by NMDA. In parallel, GPR55 activation was able to reduce the number of microglia in the dentate gyrus. These neuroprotective effects vanished however in microglia depleted OHSCs as well as in OHSC transfected with Gpr55 siRNA, indicating a strong involvement of microglia in GPR55 mediated neuroprotection.
In summary, the present study found a strong time-dependent and anterograde mechanism of action of eCB after long-range projection damage and provided further evidence for the neuroprotective properties of eCB. The potential cannabinoid receptor 3 (GPR55) mediates neuronal protection on behalf of microglia.
An overexpression of the E3 ubiquitin ligase TRIM25 is implicated in several human cancers and frequently correlates with a poor prognosis and occurrence of therapy resistance in patients. Previous studies of our group have identified the mRNA encoding the pro-apoptotic caspase-2 as a direct target of the ubiquitous RNA binding protein human antigen R (HuR). The constitutive HuR binding observed in colon carcinoma cells negatively interferes with the translation of caspase-2 mainly through binding to the 5' untranslated region (UTR) of caspase-2 and thereby confers an increased survival of tumor cells. The main objective of this thesis was to unravel novel regulatory proteins critically involved in the control of caspase-2 translation and their impact on therapeutic drug resistance of human colon carcinoma cells. By employing RNA affinity chromatography in combination with mass-spectrometry, among several putative caspase-2 mRNA binding proteins, we have identified the tripartite motif-containing protein 25 (TRIM25) as novel caspase-2 translation regulatory protein in colon carcinoma cells. The constitutive TRIM25 binding to caspase-2 mRNA in two different human colorectal carcinoma cell lines was validated by ribonucleoprotein (RNP)-immunoprecipitation (RIP)-RT-PCR assay and by means of biotin-labeled RNA-pull-down assay. Since caspase-2 is a caspase which is particularly involved in the DNA-damage-induced apoptosis, I tested the functional relevance of negative caspase-2 regulation by TRIM25 for chemotherapeutic drug-induced cell death of different adenocarcinoma cells by RNA interference (RNAi)- mediated loss-of-function and gain-of-function approaches. In the first part of the thesis, I could demonstrate that transient silencing of TRIM25 caused a significant increase in caspase-2 protein levels without affecting the amount of corresponding mRNAs. Mechanistically, the TRIM25 silencing-triggered increase in caspase-2 was totally impaired by cycloheximide, indicating that the stimulatory effects on caspase-2 levels depend on protein synthesis. This finding was corroborated by RNP/polysomal fractionation, which revealed that the transient knockdown of TRIM25 caused a significant redistribution of caspase-2 transcripts from the fraction of RNP particles to that from translationally active polyribosomes.
The second part of my thesis aimed at the elucidation of the functional consequences of the negative caspase-2 regulation by TRIM25 for enhanced tumor cell survival. Thereby, I found that the siRNA-mediated knockdown of TRIM25 caused a significant increase in the chemotherapeutic drug-induced cleavage of caspase-3 and to elevations in cytoplasmic cytochrome c levels implicating that TRIM25 depletion did mainly affect the intrinsic apoptotic pathway. Concordantly, the ectopic expression of TRIM25 caused a reduction in caspase-2 protein levels, concomitant with an attenuated sensitivity of tumor cells to doxorubicin.
To test the functional impact of caspase-2 in the TRIM25 depletion-dependent sensitization to drug-induced apoptosis, I employed a siRNA-mediated knockdown of caspase-2. Interestingly, the strong induction of caspase-3 and -7 cleavage after doxorubicin treatment was fully impaired after the additional knockdown of caspase-2, indicating the sensitizing effects by TRIM25 knockdown depend on caspase-2.
Data from this thesis identified the TRIM25 as a novel RNA-binding protein of caspase-2 mRNA, which negatively interferes with the translation of caspase-2 and which functionally contributes to chemotherapeutic drug resistance of colon carcinoma cells. Interfering with the negative TRIM25-caspase-2 axis may represent a promising therapeutic avenue for sensitizing colorectal cancers to conventional anti-tumor therapies.
Natural science is only just beginning to understand the complex processes surrounding transcription. Epitranscriptional regulation is in large parts conveyed by transcription factors (TFs) and two recently discovered small RNA (smRNA) species: microRNAs (miRNAs) and transfer RNA fragments (tRFs). As opposed to the fairly well-characterised function of TFs in shaping the phenotype of the cell, the effects and mechanism of action of smRNA species is less well understood. In particular, the multi-levelled combinatorial interaction (many-to-many) of smRNAs presents new challenges to molecular biology. This dissertation contributes to the study of smRNA dynamics in mammalian cells in several ways, which are presented in three main chapters.
I) The exhaustive analysis of the many-to-many network of smRNA regulation is reliant on bioinformatic support. Here, I describe the development of an integrative database capable of fast and efficient computation of complex multi-levelled transcriptional interactions, named miRNeo. This infrastructure is then applied to two use cases. II) To elucidate smRNA dynamics of cholinergic systems and their relevance to psychiatric disease, an integrative transcriptomics analysis is performed on patient brain sample data, single-cell sequencing data, and two closely related in vitro human cholinergic cellular models reflecting male and female phenotypes. III) The dynamics between small and large RNA transcripts in the blood of stroke victims are analysed via a combination of sequencing, analysis of sorted blood cell populations, and bioinformatic methods based on the miRNeo infrastructure. Particularly, importance and practicality of smRNA:TF:gene feedforward loops are assessed.
In both analytic scenarios, I identify the most pertinent regulators of disease-relevant processes and biological pathways implicated in either pathogenesis or responses to the disease. While the examples described in chapters three and four of this dissertation are disease-specific applications of miRNeo, the database and methods described have been developed to be applicable to the whole genome and all known smRNAs.
HIV vaccine preclinical testing is difficult because HIV’s only relevant hosts are humans and no correlates of protection are known. To this end, we are working on the humanization of different mouse strains with human peripheral blood mononuclear cells (PBMCs) as well as human hematopoietic stem cells (HSC) to generate a useful small animal model.
We generated immune deficient mice (NOD Scid IL2gc -/- /NOD Rag1-/- IL2gc -/-) expressing human MHC class II (HLA-DQ8) on a mouse class II deficient background (Ab-/-). Here, the human HLA-DQ8 should interact with the matching T cell receptors of transferred matching human PBMCs and therefore could support the functionality of the transferred human CD4+ cells in the mice.
Mice that were adoptively transferred with human HLA-DQ8 PBMCs only showed engraftment of CD3+ T cells. Surprisingly, the presence of HLA class II did not significantly change the repopulation rates in the mice. Also, the presence of HLA class II did not advance B cell engraftment, such that humoral immune responses were undetectable. However, the overall survival of DQ8-expressing mice was significantly prolonged, compared to mice expressing mouse MHC class II molecules, and correlated with an increased time span until onset of GvHD.
To avoid GVHD and to increase and maintain the level of human cell reconstitution over a long period of time, the same mouse strains were reconstituted with human HSC. Compared to PBMC-repopulated mice, HSC-reconstituted mice develop almost all subpopulations of the human immune system detectable at week 12 after HSC transfer. These mice developed adaptive immune responses after Tetanus Toxoide (TT) immunizations. In addition, we are testing the susceptibility of these humanized mice to different HIV strains with a detailed look at immune responses.
To this day, stroke is the leading cause of death and disability worldwide. Due to increasing age of the world population and poor lifestyle, the incidence is further rising. Besides mechanical thrombectomy as a surgical option, there is a lack of therapeutic options with recombinant tissue plasminogen activator (rt-PA) being the only approved drug for treatment for ischemic stroke. However, there are various problems that make the administration of rt-PA difficult. In particular, it can only be given for ischemic (not hemorrhagic) stroke, and there is a narrow time frame of 4.5 hours after onset of stroke, in which it can be successfully applied. While the success rates of combined thrombectomy with rt-PA are around 60%, less than 5% of patients receive this therapy.
ß-Hydroxybutyrate (BHB) is a ketone body that is formed in high amounts during fasting and lipolysis. Ketone bodes and the ketogenic diet have been shown to have neuroprotective properties in neurodegenerative diseases. In prior work of our group, the ketogenic diet was shown to have beneficial effects in mice after transient ischemia. In the present work, a single dose of BHB was tested for beneficial effects. For this purpose, microdialysis was used to demonstrate that BHB can cross the blood-brain barrier. For the next series of experiments, transient cerebral ischemia was induced in mice for 90 minutes by unilaterally occluding the middle cerebral artery (MCAO) with a silicone-covered filament. Behavioral tests one day after BHB administration showed that the moderate dose of 30 mg/kg, given immediately after reperfusion, improved the neurological score significantly whereas a lower (10 mg/kg) and a higher dose (100 mg/kg) had no effects The main part of the experiments focused on mitochondrial respiration as a potential mechanism of action for BHB. In isolated mitochondria from mouse brain, BHB (1-10 mM) was able to stimulate mitochondrial respiration stronger than pyruvate, but not as strong as succinate.. In the following experiments, MCAO was induced in vivo, and mitochondria were isolated and investigated ex vivo. Experiments were conducted 60 minutes, 24 hours, 72 hours, and 7 days after cerebral ischemia and reperfusion. Besides mitochondrial respiration (normalized to mitochondrial protein content or citrate synthase activity), several other parameters were monitored: the development of bodyweight throughout the experiment, citrate synthase activity, plasma metabolites and behavior to assess motor functions. Three behavioral tests were conducted: first, the Corner test, an experiment for measuring the extent of unilateral movement. Here, if a stroked mouse is put into a narrow corner (30°), it is most likely to turn unilaterally to the right, whereas an unimpaired mouse will turn to both sides randomly. From a total of 10 turns, a laterality index was calculated. Second, in the Chimney test, the mouse walks heads first into a tube. Once it reaches the end, the tube is tipped 90 degrees to stand on the table vertically. Motorically impaired animals have difficulties crawling backwards up to the top of the tube. The experiment was stopped if an animal did not reach the top of the tube within 60 seconds. Third, in the Rotarod test, the mouse is placed on a rotating beam on which it is supposed to walk for at least 60 seconds, and the time when the animal falls off the rotating tube is measured.
All animals that had undergone ischemia showed massive weight loss until 72 hours after reperfusion. Weight loss then stagnated and there was a trend of increasing weight 7 days after reperfusion. The behavioral analysis showed that 24 hours after reperfusion, BHB-treated animals performed significantly better in the Corner test, meaning their moving patterns were more heterogeneous than those of saline-treated animals and in the Chimney test. 72 hours after reperfusion, BHB-treated animals still performed significantly better in the Chimney test, but 7 days after reperfusion, the performances of BHB- and saline-treated animals were no longer different from each other in any of the behavioral tests. In separate experiments, the plasma metabolites glucose, lactate, and pyruvate were changed in the animals that had undergone ischemia but were not affected by BHB administration.
Mitochondrial respiration was tested at four time points after the administration of BHB after reperfusion – 60 minutes, 24 hours, 72 hours, and 7 days after transient cerebral ischemia. 60 minutes later, data showed an increase of oxygen consumption of the complexes I and II. OxPhos was also increased but the effect at this point, did not reach statistical significance. 24 hours after reperfusion, this effect was consolidated: complex I, complex II and OxPhos respiration were significantly improved in the BHB-treated group compared to saline...
Alzheimer’s disease (AD) is the major cause of dementia. It is characterized by the accumulation of abnormal proteins (amyloid-β plaque and neurofibrillary tangles) leading to loss of synapses, dendrites, neurons, memory and cognition. Sporadic late-onset AD is the major type of AD characterized by unclear etiology and a lack of disease-modifying therapy. To understand this disease, an alternative AD hypothesis has been proposed: AD may resemble diabetes in the brain or “diabetes type 3”. This hypothesis is supported by the fact that (1) brain glucose hypometabolism precedes AD clinical symptoms and (2) diabetes increases the risk of AD. To test this hypothesis, wild-type rats receiving intracerebroventricular administration of streptozotocin (icv-STZ) were used as a model. Streptozotocin (STZ) is a glucosamine-nitrosourea compound commonly used to induce experimental diabetes by peripheral administration. A similar pathological mechanism to peripheral STZ is then proposed to explain icv-STZ toxicity: insulin receptor signaling impairment results in glucose hypometabolism leading to cognitive deficits.
Objective: Icv-STZ model seems promising as a toxin-induced, non-transgenic AD model with the possibility to connect AD and diabetes mellitus (DM), one of the risk factors for AD. However, the mechanisms of how icv-STZ induced AD-like symptoms are unclear. Therefore, using microdialysis as the main technique, we tested 2 AD hypotheses in this model: (1) the glucose hypometabolism as an alternative AD hypothesis and (2) the cholinergic deficit as an important characteristic of AD pathology. Hippocampus was chosen because cholinergic function in this region is severely affected in AD. In comparison, the striatum was chosen because it contains cholinergic interneurons and is less affected in AD.
Methods: In this study, we used male Wistar rats of 190-220 g body weight (5 weeks of age). The rats were injected intracerebrally with STZ at a dose of 3 mg/kg (2x1.5 mg/kg; „high dose“) and 0.6 mg/kg („low dose“) with saline as control. After 21 days, samples were collected to investigate cholinergic and metabolic changes using histology, biochemistry, and neurochemistry. Brain injury was confirmed using GFAP staining and Fluoro jade staining in the hippocampus. Mitochondrial toxicity was investigated by measurement of mitochondrial
respiratory function in both hippocampus and striatum. Cholinergic markers such as acetylcholinesterase (AChE) activity, choline acetyltransferase (ChAT) activity, and choline transporter (CHT-1) activity, commonly known as high-affinity choline uptake (HACU), were measured in both hippocampus and striatum using a spectrophotometer and a scintillator.
Microdialysis is the main technique in our study. It was done in awake animals under behavioral or pharmacological stimulation. We used a self-built probe with a semi-permeable membrane (pore size of 30 kDa) that was implanted in either hippocampus or striatum. The probes were then perfused with artificial cerebrospinal fluid (aCSF) supplemented with 0.1 μM neostigmine for extracellular acetylcholine level measurement. During the perfusion, small hydrophilic compounds from brain extracellular space diffuse into the dialysates. Dialysates of 15 minutes intervals were collected for 90 minutes and used for analysis. After collection of dialysates for the first 90 minutes (basal data), rats were moved to an open field box (35x32x20 cm) for behavioral stimulation. After collection of the second 90 minute dialysates, the rats were transferred back to the microdialysis cage and dialysates were collected for another 90 minutes. On day 2, after collection of dialysates under basal conditions, 1 μM scopolamine was added to the perfusion solution for stimulation of acetylcholine release. The dialysates were also collected for 90 min followed by another 90 min of dialysis without scopolamine. The microdialysate samples were then analyzed as follows. ACh level was measured by HPLC-ECD. Glucose metabolites (glucose, lactate, pyruvate) were measured by a CMA-600 microanalyzer. An alternative energy metabolite (beta-hydroxybutyrate/BHB) was measured by GC-MS. Choline and glycerol as membrane breakdown markers were also measured by HPLC-ECD and CMA-600 microanalyzer, respectively. Markers of oxidative stress (isoprostanes) were measured using a commercially available ELISA kit.
...
Computational oral absorption models, in particular PBBM models, provide a powerful tool for researchers and pharmaceutical scientists in drug discovery and formulation development, as they mimic and can describe the physiologically processes relevant to the oral absorption. PBBM models provide in vivo context to in vitro data experiments and allow for a dynamic understanding of in vivo drug disposition that is not typically provided by data from standard in vitro assays. Investigations using these models permit informed decision-making, especially regarding to formulation strategies in drug development. PBBM models, but can also be used to investigate and provide insight into mechanisms responsible for complex phenomena such as food effect in drug absorption. Although there are obviously still some gaps regarding the in silico construction of the gastrointestinal environment, ongoing research in the area of oral drug absorption (e.g. the UNGAP, AGE-POP and InPharma projects) will increase knowledge and enable improvement of these models.
PBBM can nowadays provide an alternative approach to the development of in vitro–in vivo correlations. The case studies presented in this thesis demonstrate how PBBM can address a mechanistic understanding of the negative food effect and be used to set clinically relevant dissolution specification for zolpidem immediate release tablets. In both cases, we demonstrated the importance of integrating drug properties with physiological variables to mechanistically understand and observe the impact of these parameters on oral drug absorption.
Various complex physiological processes are initiated upon food consumption, which can enhance or reduce a drug’s dissolution, solubility, and permeability and thus lead to changes in drug absorption. With improvements in modeling and simulation software and design of in vitro studies, PBBM modeling of food effects may eventually serve as a surrogate for clinical food effect studies for new doses and formulations or drugs. Furthermore, the application of these models may be even more critical in case of compounds where execution of clinical studies in healthy volunteers would be difficult (e.g., oncology drugs).
In the fourth chapter we have demonstrated the establishment of the link between biopredictive in vitro dissolution testing (QC or biorelevant method) PBBM coupled with PD modeling opens the opportunity to set truly clinically relevant specifications for drug release. This approach can be extended to other drugs regardless of its classification according to the BCS.
With the increased adoption of PBBM, we expect that best practices in development and verification of these models will be established that can eventually inform a regulatory guidance. Therefore, the application of Physiologically Based Biopharmaceutical Modelling is an area with great potential to streamline late-stage drug development and impact on regulatory approval procedures.